Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Descartes-08 in Myasthenia gravis. The expected timing is based on the latest available company guidance and may change.
AURORA trial. 5/22/24- RMAT designation. 12/3/24- Reported updated Ph2b data & present at Cell Therapy Summit. 12/3/24- Updated Ph2b results. 5/30/25- First patient enrolled. 11/06/25:- Enrollment on track in Ph3 AURORA MG trial. Trial completion expected by Mid-2027. 03/09/26:- Enrollment continues in Ph3 AURORA MG trial; completion supported into Mid-2027. 04/30/26:- Enrollment continues in Ph3 AURORA MG trial; cash runway expected to support trial completion into Mid-2027. 08/06/26:- AURORA Ph3 data expected Q1 2027; BLA planned Mid-2027.
Verification
Confirm timing and program details against the company announcement or filing.